IMPACT Therapeutics, Inc. Class H(HK:7630)
HK$8.10-0.62 (-7.06%)
HK:7630
IMPACT Therapeutics, Inc. Class H financials statements
HK$8.10
At close:-0.62 (-7.06%)
Want to see HK:7630 full AI Analyst Report?
IMPACT Therapeutics, Inc. Class H (7630) Ratios
IMPACT Therapeutics, Inc. Class H Ratios
HK:7630's free cash flow for Q2 2026 was $3.53M. For the 2026 fiscal year, HK:7630's free cash flow was decreased by $-22.57K and operating cash flow was $3.55M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 3.08 | 4.18 | 0.81 |
| Quick Ratio | 2.82 | 4.13 | 0.81 |
| Cash Ratio | 2.47 | 2.57 | 0.74 |
| Solvency Ratio | -0.22 | -0.22 | 0.03 |
| Operating Cash Flow Ratio | -0.89 | -0.98 | 0.06 |
| Short-Term Operating Cash Flow Coverage | -25.54 | -48.93 | 0.00 |
| Net Current Asset Value | $ -138.71M | $ -103.91M | $ -14.54M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 2.58 | 2.22 | 0.00 |
| Debt-to-Equity Ratio | -0.90 | -1.16 | 0.00 |
| Debt-to-Capital Ratio | -8.98 | 7.26 | 0.00 |
| Long-Term Debt-to-Capital Ratio | -8.44 | 7.64 | 0.00 |
| Financial Leverage Ratio | -0.35 | -0.52 | -3.25 |
| Debt Service Coverage Ratio | -3.11 | -3.36 | -35.46 |
| Interest Coverage Ratio | -3.35 | -3.74 | -49.53 |
| Debt to Market Cap | 0.08 | 0.11 | 0.00 |
| Interest Debt Per Share | 0.48 | 0.63 | 0.00 |
| Net Debt to EBITDA | -2.75 | -3.23 | 13.60 |
| Profitability Margins | |||
| Gross Profit Margin | 84.20% | 75.53% | 96.58% |
| EBIT Margin | -601.22% | -593.78% | -12.02% |
| EBITDA Margin | -589.52% | -573.94% | -8.61% |
| Operating Profit Margin | -601.22% | -619.28% | -12.02% |
| Pretax Profit Margin | -773.63% | -759.39% | -8.48% |
| Net Profit Margin | -773.64% | -759.40% | 1.56% |
| Continuous Operations Profit Margin | -773.64% | -759.40% | -8.48% |
| Net Income Per EBT | 100.00% | 100.00% | -18.43% |
| EBT Per EBIT | 128.68% | 122.62% | 70.50% |
| Return on Assets (ROA) | -86.14% | -66.74% | 1.19% |
| Return on Equity (ROE) | 30.08% | 34.87% | -3.87% |
| Return on Capital Employed (ROCE) | -97.47% | -70.70% | 44.34% |
| Return on Invested Capital (ROIC) | -95.95% | -70.28% | 44.34% |
| Return on Tangible Assets | -87.36% | -67.35% | 1.21% |
| Earnings Yield | -2.78% | -3.29% | 0.07% |
| Efficiency Ratios | |||
| Receivables Turnover | 5.00 | 0.00 | 0.00 |
| Payables Turnover | 0.12 | 0.12 | 0.14 |
| Inventory Turnover | 0.22 | 1.92 | 0.00 |
| Fixed Asset Turnover | 6.25 | 3.72 | 145.72 |
| Asset Turnover | 0.11 | 0.09 | 0.76 |
| Working Capital Turnover Ratio | 0.15 | 0.32 | 0.00 |
| Cash Conversion Cycle | -1346.25 | -2769.87 | -2671.70 |
| Days of Sales Outstanding | 72.94 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 1672.94 | 189.89 | 0.00 |
| Days of Payables Outstanding | 3092.13 | 2959.76 | 2671.70 |
| Operating Cycle | 1745.88 | 189.89 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -0.05 | -0.06 | 0.02 |
| Free Cash Flow Per Share | -0.05 | -0.06 | 0.02 |
| Dividend Paid and CapEx Coverage Ratio | -63.50 | -50.94 | 63.79 |
| Capital Expenditure Coverage Ratio | -63.50 | -50.94 | 63.79 |
| Operating Cash Flow Coverage Ratio | -0.11 | -0.10 | 0.00 |
| Operating Cash Flow to Sales Ratio | -2.51 | -2.57 | 0.09 |
| Free Cash Flow Yield | -0.91% | -1.14% | 0.39% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -35.85 | -30.39 | 1519.99 |
| Price-to-Sales (P/S) Ratio | 278.67 | 230.77 | 23.74 |
| Price-to-Book (P/B) Ratio | -10.84 | -10.60 | -58.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -109.45 | -87.93 | 258.55 |
| Price-to-Operating Cash Flow Ratio | -111.17 | -89.65 | 254.50 |
| Price-to-Earnings Growth (PEG) Ratio | 2.15 | 0.01 | 0.00 |
| Enterprise Value Multiple | -50.02 | -43.43 | -262.23 |
| Enterprise Value | 1.57B | 1.17B | 751.03M |
| EV to EBITDA | -50.02 | -43.43 | -262.23 |
| EV to Sales | 294.87 | 249.29 | 22.57 |
| EV to Free Cash Flow | -115.81 | -94.98 | 245.80 |
| EV to Operating Cash Flow | -117.64 | -96.85 | 241.95 |
| Tangible Book Value Per Share | -0.50 | -0.51 | -0.10 |
| Shareholders’ Equity Per Share | -0.50 | -0.51 | -0.09 |
| Tax and Other Ratios | |||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.02 | 0.02 | 0.23 |
| Net Income Per Share | -0.15 | -0.18 | 0.00 |
| Tax Burden | 1.00 | 1.00 | -0.18 |
| Interest Burden | 1.29 | 1.28 | 0.71 |
| Research & Development to Revenue | 4.70 | 5.78 | 0.91 |
| SG&A to Revenue | 2.15 | 1.16 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.32 | 0.34 | 5.97 |
Currency in USD

